P818 Prevalence and risk factors of comorbid immune-mediated diseases in patients with inflammatory bowel disease: A nationwide population-based study in South Korea

Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

“…The pooled prevalence of PSC in patients with IBD, based on 64 studies, which contained 776,700 patients was 2.16% (95% CI 1.76%-2.60%; I 2 =99.1%, p<0.0001) (Table 1). 10,11, The lowest prevalence of PSC reported in patients with IBD was 0.12% in one Korean study, 66 while the highest was 10.97%, reported in a Finnish study (Supplementary Table 1 and Figure 2). 10 Overall, the highest pooled prevalence of PSC in patients with IBD was observed in South America (3.83%; 95% CI 2.48%-5.46%, I 2 =64.3%, p=0.06), and the lowest in Southeast Asia (0.60%; 95% CI 0.34%-0.94%, I 2 =94.1%, p<0.0001) (Table 2).…”

“…When we considered UC, CD, or IBD-U separately, pooled prevalence of PSC was 2.47% (95% CI 1.92%-3.08%; I 2 =99.2%, p<0.0001) in 43 studies containing 566,178 patients with UC, 10,11,[19][20][21][22][23][24][25][26][27][28][29][31][32][33]36,[40][41][42]44,45,[47][48][49][50]52,[56][57][58][59][60][61]63,66,[68][69][70]72,74,[78][79][80] 0.96% (95% CI 0.69%-1.28%; I 2 =91.7%, p<0.0001) in 28 studies recruiting 156,943 patients with CD, 10,22,24,29,30,32,33,…”

“…10,63,80 The OR in patients with UC, versus patients with CD, in 25 studies that reported prevalence in both UC and CD within the same study population, was 1.69 (95% CI 1.24-2.29), with moderate heterogeneity (I 2 =66.5%, p<0.0001), but no funnel plot asymmetry (Egger test, p=0.36). 10,22,24,29,32,33,36,41,[47][48][49][50]52,56,58,59,61,63,66,69,72,74,[78][79][80] In patients with IBD-U, versus UC, it was 3.27 (95% CI Seventeen studies reported data separately in patients with UC 11,19,45,47,49,50,56,57,60,63,66,69,70,72,74,78,80 and 13 in CD, 37,39,…”